Author
Listed:
- Kan Li
(Rutgers, the State University of New Jersey)
- Michael J. Rudy
(University of Colorado School of Medicine)
- Yanmei Hu
(Rutgers, the State University of New Jersey)
- Haozhou Tan
(Rutgers, the State University of New Jersey)
- George Lambrinidis
(National and Kapodistrian University of Athens, Panepistimiopolis-Zografou)
- Xiangmeng Wu
(The University of Arizona)
- Kyriakos Georgiou
(National and Kapodistrian University of Athens, Panepistimiopolis-Zografou)
- Bin Tan
(Rutgers, the State University of New Jersey)
- Joshua Frost
(University of Colorado School of Medicine)
- Courtney Wilson
(University of Colorado School of Medicine)
- Penny Clarke
(University of Colorado School of Medicine)
- Antonios Kolocouris
(National and Kapodistrian University of Athens, Panepistimiopolis-Zografou)
- Qing-yu Zhang
(The University of Arizona)
- Kenneth L. Tyler
(University of Colorado School of Medicine
University of Colorado School of Medicine
University of Colorado School of Medicine
Rocky Mountain VA Medical Center)
- Jun Wang
(Rutgers, the State University of New Jersey)
Abstract
Enterovirus D68 (EV-D68) is a respiratory virus that often causes mild to moderate respiratory illnesses and, in severe cases, can lead to paralysis and rarely death, mainly in children. There is currently no vaccine or antiviral for EV-D68. Here, we report the rational design of viral 2 C inhibitors for treating EV-D68 infection-induced paralysis in a neonatal mouse model. Viral 2 C protein is a multi-functional protein vital for viral replication. Structure-based drug design identifies Jun6504 showing potent and broad-spectrum antiviral activity against multiple strains of EV-D68, EV-A71, and CVB3, as well as favorable in vitro and in vivo pharmacokinetic properties. In a neonatal mouse model of EV-D68 infection, Jun6504 significantly improves paralysis score and weight gain when administered immediately or 24 hours post-infection. Jun6504 also reduces viral titers in the spinal cord and the infected quadriceps muscle. Collectively, Jun6504 represents a promising candidate for further development as an EV-D68 antiviral.
Suggested Citation
Kan Li & Michael J. Rudy & Yanmei Hu & Haozhou Tan & George Lambrinidis & Xiangmeng Wu & Kyriakos Georgiou & Bin Tan & Joshua Frost & Courtney Wilson & Penny Clarke & Antonios Kolocouris & Qing-yu Zha, 2025.
"A rationally designed 2C inhibitor prevents enterovirus D68-infected mice from developing paralysis,"
Nature Communications, Nature, vol. 16(1), pages 1-18, December.
Handle:
RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-61083-8
DOI: 10.1038/s41467-025-61083-8
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-61083-8. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.